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Abstract
Background: An anti-reflux catheter (ARC) may increase the tumor absorbed dose during radioembolization (RE) by
elimination of particle reflux and its effects on hemodynamics. Since the catheter is fixed in a centro-luminal
position, it may also increase the predictive accuracy of a scout dose administration before treatment. The purpose
of the SIM trial is to compare the effects of ARC use during RE with holmium-166 (166Ho) microspheres in patients
with colorectal liver metastases (CRLM), with the use of a standard end-hole microcatheter.
Methods/Design: A within-patient randomized controlled trial (RCT) will be conducted in 25 patients with
unresectable chemorefractory liver-dominant CRLM. Study participants will undergo a 166Ho scout dose procedure
in the morning and a therapeutic procedure in the afternoon. The ARC will be randomly allocated to the left/right
hepatic artery, and a standard microcatheter will be used in the contralateral artery. SPECT/CT imaging will be
performed for quantitative analyses of the microsphere distribution directly after the scout and treatment
procedure. Baseline and follow-up investigations include 18F-FDG-PET + liver CT, clinical and laboratory
examinations. The primary endpoint is the comparison of tumor to non-tumor (T/N) activity ratio in both groups.
Secondary endpoints include comparisons of mean absorbed dose in tumors and healthy liver tissue, infusion
efficiency, the predictive value of 166Ho scout dose for tumor response. In the entire cohort, a dose-response
relationship, clinical toxicity, and overall survival will be assessed. The sample was determined for the expectation
that the ARC will increase the T/N ratio by 25 % (mean T/N ratio 2.0 vs. 1.6).
Discussion: The SIM trial is a within-patient RCT that will assess whether 166Ho RE treatment can be optimized by
using an ARC.
Trial registration: The SIM trial is registered at clinicaltrials.gov (NCT02208804). Registered on 31 July 2014.
Background
Hepatic radioembolization (RE) has evolved to a standard-
of-care therapy for patients with irresectable and chemore-
fractory colorectal cancer liver metastases (CRLM). During
this treatment, radioactive microspheres are injected in the
hepatic arteries to irradiate liver tumors from within,
leading to local disease control [1]. However, treatment
efficacy and predictability of the treatment effect can still be
optimized, since the radiation dose to individual tumors is
often inadequate and this cannot be predicted beforehand
due to the lack of a reliable surrogate particle (scout dose)
for routinely used yttrium-90 (90Y) microspheres [2].
Holmium-166 (166Ho) microspheres have been developed
and clinically validated as a new microsphere for RE [3].
Besides β-radiation, these microspheres also emit low-
energy γ-radiation and have paramagnetic characteristics,
allowing for visualization and quantitative assessment of
the microsphere distribution on single-photon emission
computed tomography (SPECT) and magnetic resonance
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imaging (MRI) [4]. Furthermore, identical 166Ho micro-
spheres can be administered as a scout dose to predict the
distribution of the therapeutic microspheres [3, 5].
Another promising development is the availability of
an anti-reflux catheter (ARC, Surefire Infusion System,
Surefire Medical Inc., Westminster, CO, USA), aiming to
increase the infusion efficiency and safety, by prevention
of reflux [6–8]. The effects on hemodynamics induced
by this catheter may improve the microsphere uptake ra-
tio between tumorous and non-tumorous liver tissue (T/
N ratio). The expanded catheter tip decreases blood
pressure downstream of the tip, which is believed to
lower the resistance that injected microspheres need to
overcome in order to reach the tumor vasculature [9].
Furthermore, the catheter tip converts blood flow from
a laminar into a turbulent pattern, which reduces the
chance of missing a target branch by proper mixing of
the microspheres in the vascular compartment. In
addition, the catheter is fixed into a centro-luminal cath-
eter position during infusion which may further increase
the accuracy of the 166Ho scout dose as a predictor for
the therapeutic 166Ho microspheres distribution [2].
In this article, we describe the study protocol of a
prospective, comparative, clinical trial with the aim to
investigate whether the ARC can be used to improve
tumor targeting as well as the predictability of the treat-
ment effect during 166Ho RE.
Methods
Hypothesis
We hypothesize that the use of the ARC increases the
posttreatment T/N activity ratio and improves the pre-
dictive value of 166Ho scout dose distribution, in com-
parison with the use of a standard microcatheter (SMC).
Study design
The SIM trial is a single-center, open-label, phase II,
within-patient randomized controlled trial (RCT). As
opposed to a conventional RCT design, patients act as
their own controls; liver lobes (right versus left lobe) are
the experimental units in this study. Patients with
bilateral, irresectable, chemorefractory, liver-dominant
CRLM will undergo two sequential procedures on the
same day, during which a scout dose and a therapy dose
of 166Ho microspheres will be administered in the left and
right hepatic artery. These separate injections can be
regarded as two separate treatments of functionally inde-
pendent liver lobes. The use of the ARC will be randomly
allocated (1:1) to the left or right functional liver lobe and
a standard microcatheter (SMC) will be used in the
contralateral side. The same catheter type will be used on
the same side during the scout and therapy procedures.
This trial will be conducted in accordance with the
principles outlined in the Declaration of Helsinki and
will follow the Consolidated Standards of Reporting
Trials (CONSORT) statement [10]. A Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) checklist is provided in Additional file 1 [11].
Study population
All patients with irresectable, chemorefractory, and liver-
dominant CRLM are eligible for participation in this trial if
they meet the following inclusion criteria: histopathologic-
ally confirmed diagnosis of adenocarcinoma of the colon or
rectum, hepatic metastases with measurable morphological
appearance (≥1 cm) on cross-sectional imaging located in
both the right and left hepatic arterial perfusion territory,
irresectable and liver-dominant disease (i.e., pathological
locoregional lymph nodes and up to five lung lesions <
1 cm are accepted), progressive disease after standard
second-line systemic treatment or no further systemic
treatment options due to severe side effects or unwilling-
ness of the patient, age ≥ 18 years. Adequate follow-up must
be logistically feasible and written informed consent must
be obtained before enrollment in the study.
Exclusion criteria are: World Health Organization
(WHO) performance score > 2, inadequate bone marrow
function (hemoglobin < 6.0 mmol/l, leukocyte count <
3.0 × 109/l, platelet count < 75 × 109/l), inadequate liver
function (bilirubin > 35 μmol/l, aspartate aminotransferase/
alanine aminotransferase > 5 × upper limit of normal) or
inadequate renal function (creatinine > 1.5 × upper limit of
normal), prior hemihepatectomy, compromised biliary
system (biliary stent or hepaticojejunostomy), Child-Pugh
score B7 or worse, active hepatitis B or C, main portal vein
thrombosis or previous portal vein embolization, severe
celiac axis stenosis, unsuitable hepatic arterial anatomy,
treatment with systemic chemotherapy within 4 weeks
prior to RE, previous participation in a study classified as
class III by a radiation safety committee, bleeding diathesis,
pregnancy or breast feeding, or any condition that prevents
safe treatment with RE.
Investigations and interventions
The flowchart in Fig. 1 shows how the investigations
and interventions in the SIM trial compare to standard
radioembolization practice with 90Y microspheres.
Baseline investigations
Patients will first undergo pretreatment investigations as
part of our routine RE workup: whole-body 18F-fluoro-
deoxyglucose positron emission tomography/computed
tomography (18F-FDG-PET/CT) to rule out extensive
extrahepatic metastases and calculate metabolic tumor
burden; dual-phase (arterial + portal phase) liver CT to
rule out other contraindications for RE, localize the liver
tumors, and assess the hepatic arterial anatomy; laboratory
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investigations and a physical examination to assess vital
functions and general condition of the patient.
Treatment planning
Eligible patients will be asked to provide informed con-
sent to participate in the study. Next, the interventional
radiologist and nuclear medicine physician will make an
individualized treatment plan (including identification of
the target vessels for selective infusion, identification of
extrahepatic branches, and determining the need for coil
embolization), based on the anatomy of the hepatic
arterial vasculature visualized on pretreatment CT
images. In all procedures, two selective injection posi-
tions (in the left and right hepatic artery) will be used to
treat the whole liver on the same day. In patients with a
variant hepatic arterial configuration, intrahepatic arter-
ial branches (for example, the segment 4 artery) may be
coil embolized to induce redistribution of blood flow
through intrahepatic collaterals, and enable the use of
two selective injection positions.
The total amount of 166Ho activity (AHo166) required
to deliver a whole liver absorbed dose of 60 Gy – the
maximum tolerable radiation dose previously deter-
mined in a phase I dose-escalation study – is calculated
using the formula:
AHo166 MBqð Þ ¼ 60 Gyð Þ
15:87x10−3 J=MBqð Þ xLiver weight Kgð Þ
Liver weight (in Kg) is determined by multiplying the
volume of the liver (measurement based on CT) with
the density of liver tissue (1.06 g/cm3). The scout
procedure always consist of 250 MBq in 60 mg of micro-
spheres (density 1.4 g/cm3), this activity is subtracted
from the activity given in the treatment procedure. The
treatment activity for each perfusion territory is fraction-
ated based on its liver volume. If coil embolization of an
intrahepatic branch is planned, the volume of its perfu-
sion territory is included in the side that is anticipated
to take over the blood supply.
Fig. 1 Flowchart of the investigations and interventions in the SIM trial. The study procedures are compared to standard radioembolization
practice with yttrium-90 (90Y) microspheres. Note that in the SIM trial, the same particle is used during the scout and therapy procedure, and
patients receive all procedures on the same day
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Scout and therapy procedures
All patients will be admitted to hospital (University Medical
Center Utrecht, The Netherlands) and will undergo a 166Ho
scout procedure the next morning, followed by the 166Ho
therapeutic procedure in the afternoon when the scout
procedure was performed successfully.
During the 166Ho scout procedure, digital subtraction
angiography (DSA) and C-arm CT imaging will be
performed to confirm adequacy of the intended injection
position(s), and rule out potential extrahepatic shunting.
Coil embolization of side branches will only be performed
when inevitable to warrant safe treatment. Nitroglycerine
200 μg is given per intra-arterial catheter to prevent vaso-
spasm. Ultimately, a scout dose (250 MBq) of 166Ho mi-
crospheres will be administered through the anti-reflux
catheter (ARC) and the SMC in the target vessels.
Next, a SPECT scan combined with a portal venous
phase liver CT will be acquired and evaluated to rule out
extrahepatic deposition of 166Ho microspheres, assess the
intrahepatic biodistribution, as well as the liver-to-lung
shunt. In the absence of extrahepatic deposition and a
significant liver-to-lung shunt (visible accumulation 166Ho
in the lung parenchyma), patients will undergo the
therapeutic procedure in the afternoon. In the case of an
unsuccessful scout procedure, the patient will be sched-
uled for a repeat procedure if possible.
During the therapeutic procedure, the calculated treat-
ment activity of 166Ho microspheres will be administered
in the same position(s) as during the scout procedure.
Patients are discharged the day after treatment. The
posttreatment SPECT (combined with a dual-phase liver
CT) is obtained approximately 5 days after treatment to
reduce the influence of detector dead time.
Follow-up investigations
A telephonic consultation will be scheduled at 2 weeks after
treatment to evaluate the patient’s general condition, and
ask for the occurrence of adverse events. One month after
treatment, patients will undergo a physical examination
and laboratory investigations for toxicity assessment. At 3-
month follow-up, this is complemented by a whole-body
18F-FDG-PET + dual-phase liver CT for tumor response
assessment, after which the study follow-up is completed.
Study objectives
The primary objective is to assess the difference in post-
treatment T/N activity ratio on SPECT/CT between ad-
ministration with the ARC and SMC.
Secondary objectives include comparison of the follow-
ing endpoints between administrations with the ARC and
SMC: mean tumor and healthy liver absorbed dose on
SPECT/CT, percentage of calculated treatment activity
administered (infusion efficiency), predictive value of the
166Ho scout dose distribution, and posttreatment tumor
response. Furthermore, the presence of a dose-response
relation between tumor absorbed dose and posttreatment
tumor response will be evaluated.
Outcome assessment
In every target vessels’ perfusion territory, the absorbed
dose on 166Ho-SPECT reconstructions will be determined
for the metastases and the healthy liver tissue [4].
Consequently, a posttreatment T/N activity ratio will be
calculated for each perfusion territory by dividing the
number of counts in tumorous and healthy liver tissue.
The predictive value of the scout dose will be assessed
by comparison of the distribution of the scout dose with
the treatment dose. The analysis will be based on tumor
and healthy liver absorbed doses on SPECT/CT analysis.
Infusion efficiency is defined as the percentage of the
prepared treatment activity that is infused. The 166Ho
activity that is not infused will be determined by measur-
ing the administration system (vial, lines, and catheters)
with a dose calibrator.
Response analysis will be performed in accordance with
the Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1 [12], for each functional liver lobe
separately. Disease control rates (percentage of liver lobes
with complete response, partial response or stable disease)
will be determined by CT evaluation at 3 months
posttreatment. Metabolic tumor response will be deter-
mined by assessing the change (relative to baseline) in total
lesion glycolysis values on 18F-FDG-PET imaging. During
the response assessment, observers will be blinded for the
catheter type used.
The relationship between tumor absorbed dose on
SPECT/CT and tumor response on both CT and 18F-
FDG-PET will be characterized on the level of perfusion
territories.
Common Terminology Criteria for Adverse Events v
4.03 will be used to describe laboratory and clinical
toxicity for the entire cohort, with specific attention for
device-related adverse events per catheter type such as the
occurrence of reflux, vasospasm, or arterial dissections.
The municipal administration will be consulted to assess
the overall survival, measured from treatment onward.
Statistical considerations
Sample size calculation
A subgroup analysis of the T/N activity ratios in seven
patients with CRLM, previously treated with 166Ho RE
using a SMC [3], showed a mean T/N ratio of 1.6
(standard deviation 0.57). Sample size calculation, based
on a two-sided paired t test for the comparison of T/N
activity concentration ratios at an alpha level of 0.05 and
power of 0.90, showed that at least 23 patients need to
be included to detect a difference of 0.4 in mean T/N
ratios (with an estimated standard deviation 0.57) in the
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ARC arm (estimated mean T/N ratio 2.0) and SMC arm
(estimated mean T/N ratio 1.6). This corresponds to a
25 % increase (considered clinically relevant) in favor of
the ARC arm. A rounded number of 25 patients will
therefore be treated in this trial. Sample size calculations
were performed with the computer program ‘PS: Power
and Sample Size Calculation’ version 3.0 for MacOsX.
Randomization
A computer-generated stratified permuted block rando
mization with varying block sizes will be used. Differ-
ence in tumor burden (<10 % or ≥ 10 %) between the
two target volumes in the liver will be used as stratifica-
tion factors to eliminate the potential influence of tumor
burden on the comparison of T/N activity ratios be-
tween catheter types.
Statistical analysis
A comparison of continuous outcome measures between
ARC and SMC infusions, such as the mean T/N activity
concentration and mean decrease in total lesion glycolysis
at 3 months posttreatment, will be performed by means of
a paired t test. Categorical outcome measures, such as
infusion efficiency and disease control rates at 3 months
posttreatment, will be compared with a McNemar’s test.
The value of the 166Ho scout dose distribution will be
assessed per catheter type. Correlation and agreement
with the 166Ho therapy dose distribution will be evaluated
with a linear regression analysis (R2) and Bland-Altman
analysis (limits of agreement), respectively. The dose-
response relationship will be evaluated by linear regression
analysis. Survival analysis by the Kaplan-Meier method
will be used to estimate the median overall survival time
for the entire cohort. The primary analyses will be per-
formed on an intention-to-treat (as randomized) basis.
A two-sided p value < 0.05 will be considered statisti-
cally significant.
Study organization
Data completeness and accuracy will be frequently
checked by the Department of Radiology and Nuclear
Medicine, University Medical Center Utrecht. An inde-
pendent clinical research associate (Julius Clinical, Zeist,
The Netherlands) will audit the trial conduct during 3–4
visits. Appointing a data safety monitoring board was
not required for this trial. As per Dutch regulations, ser-
ious adverse events, serious adverse device effects, and
protocol violations are recorded and reported to the in-
stitutional review board. There are no stop rules in this
study. No interim analysis is planned.
Discussion
In patients with advanced colorectal cancer, liver metas-
tases are the primary cause of morbidity and mortality.
Unfortunately, only a minority of patients is a candidate
for surgical resection with curative intent. Patients with
irresectable disease will first receive palliative systemic
therapy. Though, despite major advances in systemic
treatment, overall survival remains disappointing in this
subgroup of patients [13, 14].
Current standard of care in the systemic treatment of
metastatic colorectal cancer is based on cytotoxic fluoro-
pyrimidines, oxaliplatin, and irinotecan, as well as tar-
geted therapy with the vascular endothelial growth
factor (VEGF)-targeted monoclonal antibody bevacizu-
mab [15–19]. There is no clear preference for sequential
exposure to these drugs during consecutive lines of
treatment or upfront combination therapy [20, 21].
When disease progression or intolerable toxicity occurs
during first-line treatment, patients will subsequently re-
ceive another regimen as second-line treatment, with
the choice of the regimen depending on the first chemo-
therapeutic agents. In the Netherlands, the first-line
regimen of choice is CAPOX-B (capecitabine, oxalipla-
tin, and bevacizumab). After initial treatment with six
cycles of CAPOX-B, maintenance therapy with capecita-
bine and bevacizumab is given until disease progression
[22]. Subsequently an irinotecan-based regimen, e.g.,
FOLFIRI (leucovorin, fluorouracil (5-FU), and irinote-
can) or irinotecan monotherapy, is indicated as second-
line therapy. Only patients with a KRAS wild-type tumor
may benefit from additional (third-line) treatment with
an epidermal growth factor receptor (EGFR)-targeted
monoclonal antibody (panitumumab or cetuximab).
Liver-directed therapy such as RE is increasingly applied
as an alternative to achieve local disease control. Currently,
two types of yttrium-90 microspheres are used in world-
wide clinical practice: resin (SIR-Spheres, SIRTeX, Lane
Cove, Australia) and glass (TheraSphere; BTG, Ottawa,
ON, Canada) yttrium-90 (90Y) microspheres. In salvage
patients with colorectal liver metastases, who have no regu-
lar treatment options left and an average life expectancy of
less than 6 months, median overall survival after RE treat-
ment with 90Y microspheres is around 12 months when
given as monotherapy or in combination with chemother-
apy [1]. Besides, treatment is generally well tolerated, with
typical clinical toxicity being limited to mild symptoms of
fatigue, abdominal pain, nausea, vomiting and/or fever
during the first 2 weeks after treatment [23].
Despite these benefits of RE, there is still room for im-
provement. Unintentional deposition of radioactive micro-
spheres in tissues other than the liver may cause serious
treatment complications. Therefore, a safety procedure is
performed in the week(s) before the actual treatment.
During this procedure, coil embolization of extrahepatic
branches may be performed and a strategic catheter
position is chosen before administering a (harmless) scout
dose of technetium-99 m-labelled macro-aggregated
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albumin (99mTc-MAA). Afterward, SPECT/CT and planar
nuclear scintigraphy are obtained to exclude the presence
of extrahepatic activity and significant liver-to-lung
shunting. The treatment procedure is typically performed
1–2 weeks later, with the administration of 90Y micro-
spheres from identical catheter positions, followed by
posttreatment imaging with bremsstrahlung SPECT/CT
or 90Y-PET/CT [24].
As a second topic of possible improvement, the intrahe-
patic distribution of therapeutic 90Y microspheres cannot
be accurately predicted in advance. The scout dose of
99mTc-MAA particles differs markedly in embolic effect,
size, weight, and number of particles infused [25], and
therefore fails to predict the intrahepatic distribution of 90Y
microspheres in most cases [26–28]. Besides, imaging of
the 90Y microspheres biodistribution itself is already a chal-
lenge due to the lack of γ-radiation emission. Traditionally,
bremsstrahlung SPECT/CT has been used for posttreat-
ment imaging, but it suffers from a low spatial resolution.
Internal-pair production-based 90Y-PET/CT has become
available as an alternative for quantitative imaging, but the
low count rate and inherent noise limit its applicability in
daily clinical care [29–31].
Third, it is generally assumed that the preferential arter-
ial vascularization of liver tumors will lead to a selective
targeting of tumorous tissue following intra-arterial
infusion of radioactive microspheres. It is known from
pathological examinations of livers treated with 90Y RE
that radioactive microspheres cluster preferentially within
the peripheral tumor vasculature. The concentration of
microspheres can be up to 200 times greater in the tumor
periphery than in the tumor center and the healthy liver
tissue [32]. Various studies have investigated dose-
response relationships in RE. The majority of these studies
found strong associations between T/N ratios, absorbed
radiation doses, tumor response and overall survival [27,
33–39]. Yet, the degree of tumor targeting, as expressed
by the T/N microsphere uptake ratio, shows marked inter-
individual variability in practice, with a reported range of
0.6–25.9 [40]. This heterogeneity in T/N uptake ratios is
likely a result of various factors, including differences in
tumor angiogenesis, microsphere characteristics, catheter
position, and flow-bound distribution physics [25, 33]. A
recent investigation demonstrated that up to 60 % of
patients with liver metastases treated with 166Ho RE had
at least one tumor that received less than or an equal
amount of radioactivity as compared to the surrounding
healthy liver tissue (T/N ≤ 1) [4]. Flamen et al., also
reported similar findings, with 38 % of the metastatic liver
lesions in their study having an unfavorable T/N uptake
ratio (<1) after RE with 90Y microspheres [39]. Since
unfavorable T/N uptake ratios cannot be predicted and
only become apparent after treatment, timely adjustments
in treatment technique are not yet feasible.
The highly variable tumor targeting is an important
clinical problem that may at least explain some of the in-
consistencies in reported tumor response rates after RE
[1, 41]. Considering the reported dose-response relation-
ship, it can be expected that improved T/N ratios will
positively affect tumor response after RE. It may also
reduce hepatotoxicity, since healthy liver tissue absorbed
dose has previously been correlated to biochemical
toxicity [37]. Improvement of T/N ratios is especially
important in CRLM, since metastases from this tumor
type are relatively hypovascular compared with other
tumor types (such as neuroendocrine tumors or uvea
melanoma), and generally exhibit low T/N ratios.
The above outlined shortcomings of current RE prac-
tice are being addressed in the SIM trial, for which trial
accrual has started as of November 2014. The distinctive
imaging capacities and availability of an identical scout
dose of 166Ho microspheres, combined with the promis-
ing effects on particle fluid dynamics facilitated by the
ARC, may result in an optimized treatment technique of
RE in patients with CRLM.
Trial status
Patient recruitment was ongoing at the time of submission.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 checklist: recommended items to
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